MyRiskTM Hereditary Cancer Test

Take the next step with MyRiskTM

Get started by downloading the provider guide or explore ordering options to bring MyRisk to your practice.

Download provider guide

.

Take the next step with MyRiskTM

Whether you’ve heard about genetic testing before or want to learn more, we can help provide in-depth information on MyRisk and your testing options.

Download patient guide

MyRiskTM Hereditary Cancer Test

Determine your patient’s best treatment options with germline testing

The MyRisk Hereditary Cancer Test helps you get the clarity you need to determine the best surgical and treatment options for your patient in 14 days or less. The multi-gene panel analyzes risk for 11 cancers to determine if your patient has a germline genetic mutation associated with an increased cancer risk.

MyRiskTM Hereditary Cancer Test

Determine your patient’s best treatment options with germline testing

The MyRisk Hereditary Cancer Test helps you get the clarity you need to determine the best surgical and treatment options for your patient in 14 days or less. The multi-gene panel analyzes risk for 11 cancers to determine if your patient has a germline genetic mutation associated with an increased cancer risk.

Germline testing can help guide treatment for your patient

Gain clarity beyond tumor testing

Somatic testing alone can have some limitations including unknown variants, limited tumor tissue, and missed large rearrangements. Germline testing gives you the clarity you need to guide treatment decisions, including targeted therapies and surgical techniques.

Guidelines recommend germline

NCCN Guidelines® recommend germline testing in the workup for patients diagnosed with, or after the confirmation of, ovarian, metastatic breast, and pancreatic cancer.

Identify risk of secondary cancers

A MyRisk germline test can provide comprehensive insights to help you and your patient reduce the occurrence of a subsequent primary cancer.

Germline testing info graphic

Who is MyRisk for?

Myriad MyRisk Hereditary Cancer Test product

MyRisk germline testing is appropriate for patients diagnosed with:

  • Breast cancer*
  • Ovarian cancer
  • Uterine cancer
  • Pancreatic cancer*
  • Endometrial cancer
  • Lung cancer
  • Gastric cancer
  • Renal cancer
  • Colorectal cancer
  • Prostate cancer
  • Skin cancer

*eligible for MyRisk STAT

MyRisk testing provides you with clear results you can trust

MyRisk germline testing assesses more than 48 genes linked to one or more of 11 cancer sites. The results will list specific mutations found, including variants of uncertain significance (VUS). A summary of medical society guidelines to guide and optimize treatment decisions will also be provided in the MyRisk Management Tool (MMT).

Positive result icon

Positive Result

A mutation has been identified.

Elevated result icon

Elevated Result

An elevated risk has been identified.

Negative result icon

Negative Result

No clinically significant mutation.

Variant of uncertain significance result icon

Variant of Uncertain Significance

Mutation of uncertain risk has been identified.

Trust MyRisk to provide you and your patient with the most accurate results

Clarity through leading variant classification

Studies have shown that over 1/3 of conflicting variant classifications may alter patients’ medical management.1 Our tests have provided definitive classification for up to 63% of variants that other labs could not.2

Clarity through leading variant classification

Studies have shown that over 1/3 of conflicting variant classifications may alter patients’ medical management.1 Our tests have provided definitive classification for up to 63% of variants that other labs could not.2

RNA analysis reduces the rate of uncertain variants

Myriad offers RNA analysis to all patients with an eligible variant of unknown significance (VUS) after MyRisk testing is complete. Myriad will notify the healthcare provider when RNA analysis could help classify variants, giving providers and patients access to this valuable tool regardless of when, where, or how their MyRisk test was submitted.

MyRisk result accuracy statistics graphic

MyRisk STAT:

Right surgery. Right answer. Right now.

There should not be a trade-off between turnaround time and receiving an accurate, comprehensive risk assessment when determining surgical treatment for patients. MyRisk STAT was developed for trusted results without the wait.

  • When you order MyRisk STAT germline testing for breast cancer patients, you will receive the report for the 10 breast cancer genes within 5-12 calendar days.
  • MyRisk STAT germline testing for pancreatic cancer patients can give you faster results for BRCA 1/2, PALB2 and 7 other genes in 5-12 calendar days.

In addition to the 10 STAT genes, all MyRisk STAT orders will receive the full Myriad MyRisk Hereditary Cancer Panel report in 14 days or less.

How to test with MyRisk

Provider completes the test request form (in the portal or via paper TRF)

Provider completes the test request form (in the portal or via paper TRF)

Patient blood or saliva sample is collected and submitted to Myriad Genetics with the test kit

Patient blood or saliva sample is collected and submitted to Myriad Genetics with the test kit

Results are sent to the ordering provider (in the portal or via mail)

Results are sent to the ordering provider (in the portal or via mail)

One simple order. Comprehensive results.

With Precise™ Oncology Solutions, you can receive results for comprehensive germline testing, tumor profiling and companion diagnostic options, including MyRisk, in one single ordering experience, getting clear, fast answers for your patients.

What to expect with every MyRisk test

Accurate

Myriad believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answer possible.

Actionable

Every MyRisk test provides actionable results within two weeks to inform more confident patient treatment and surgical decisions.

Affordable

Myriad is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.

MyRisk resources

Patients with government payers (Medicare, Medicare Advantage, TriCare) are not eligible for MyRisk STAT.

References:
  1. Balmana J, 2016: 26% of variants had conflicting classifications from different commercial labs.
  2. Gradishar W, et al. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. The Oncologist (2017).
MyRiskTM Hereditary Cancer Test